Liver cancer
Conditions
Interventions
taVNS group:Using the transauricular vagus nerve stimulator (manufacturer: Changzhou Ruishenan Medical Devices Co., Ltd., approval number 20212090050, applied for by the hospital equipment department)
Control group:Conventional treatment and care: After surgery, the patient uses a patient-controlled analgesia pump
symptoms such as pain, nausea, and vomiting are treated accordingly
the patient gets out of bed for activities on the first day after surgery.
Sponsors
The First Affiliated Hospital of Zhejiang University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Pathological results confirm a diagnosis of liver cancer; 2. Patients newly diagnosed and hospitalized for treatment; 3.Patients whose treatment method is liver cancer resection surgery; 4.American Society of Anesthesiologists (ASA) classification I~II; 5. Aware of their medical condition; 6. Able to understand the research process and the use of various assessment scales, and can communicate effectively with researchers; 7. Informed consent, voluntarily participate in this project, and willing to undergo postoperative follow-up surveys.
Exclusion criteria
Exclusion criteria: 1.Related to the subjects : ( 1 ) Refusing to sign the test consent ; ( 2 ) Patients with previous history of abdominal surgery, including esophagectomy, gastrectomy, hepatectomy and pancreatectomy ; ( 3 ) Ear skin injury or inflammation, known to the electrode gel, silica gel or metal ( such as stainless steel, silver ) have a history of contact allergy ; ( 4 ) patients with chronic pain and long-term use of opioids ; ( 5 ) Patients with a history of heart disease, severe liver and kidney dysfunction ; ( 6 ) Patients with severe cardiovascular and cerebrovascular diseases, dementia and inability to communicate ; ( 7 ) Neuromuscular disease ; ( 8 ) Refuse to use analgesic pump ; ( 9 ) Patients who received vagus nerve stimulation or acupuncture treatment within 1 month before the study ; ( 10 ) is participating in any other interventional clinical research. 2.Related to the lesion : ( 1 ) Inconsistent oncological characteristics : patients with advanced liver cancer with extrahepatic metastasis ( such as lung, bone, lymph nodes, etc. ) found by imaging or surgery ; patients with complex surgery requiring combined multiple organ resection ( such as combined colon resection, adrenalectomy, etc. ). ( 2 ) Poor basic liver function : with severe cirrhosis, Child-Pugh classification is C grade. Patients with medium to large ascites and difficult to control. He had a history of hepatic encephalopathy. ( 3 ) Combined with other gastrointestinal diseases affecting gastrointestinal function : combined with inflammatory bowel disease, severe gastroparesis diagnosis. Complicated with untreated peptic ulcer, pyloric obstruction or intestinal obstruction. ( 4 ) Combined with other serious systemic diseases : combined with uncontrolled systemic infection or sepsis. Complicated with uncontrolled diabetes ( such as recent ketoacidosis ) or with severe diabetic autonomic neuropathy. It was diagnosed as active autoimmune disease and requires continuous immunosuppressive therapy. 3.Exclusion criteria related to combined medication : ( 1 ) Drugs that affect gastrointestinal motility were used at a specific time before the study began. For example, prokinetic drugs ( such as metoclopramide, domperidone, mosapride, etc. ) or antiemetic drugs ( such as ondansetron, granisetron ) were used within 1 week before randomization. ( 2 ) Recent use of drugs that affect the inflammatory response before surgery. For example, glucocorticoids ( such as prednisone ) or high-dose non-steroidal anti-inflammatory drugs ( NSAIDs ) were systematically used within 2 weeks before the study. ( 3 ) Patients who are using anticoagulant or antiplatelet drugs ( such as warfarin, rivaroxaban, clopidogrel, aspirin ) and cannot be safely discontinued as required during the perioperative period. ( 4 ) The researcher considers any other combination medication that may seriously affect the evaluation of the study, confuse the results of the study, or increase the risk of the subject. Consolidated medications that seriously affect research evaluation, confuse research results, or increase the risk of subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The first postoperative exhaust time;Postoperative first defecation time;Postoperative recovery time of bowel sounds; | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain score;Incidence of postoperative nausea and vomiting;Quality of recovery;Sleeping condition;Gastrointestinal function score;Negtive emotion;Safety Indicators ( Adverse Reactions );Economic indicators; | — |
Countries
China
Contacts
Public ContactLifang Bian
The First Affiliated Hospital of Zhejiang University School of Medicine
Outcome results
None listed